

World Journal of *Obstetrics and Gynecology*

World J Obstet Gynecol 2013 February 10; 2(1): 1-7



Editorial Board

2012-2016

The World Journal of Obstetrics and Gynecology Editorial Board consists of 178 members, representing a team of worldwide experts in obstetrics and gynecology. They are from 40 countries, including Australia (6), Austria (2), Belgium (5), Brazil (5), Canada (2), Chile (1), China (9), Egypt (3), Finland (2), France (2), Germany (1), Greece (11), Hungary (1), India (3), Iran (3), Israel (6), Italy (13), Japan (6), Jordan (2), Lithuania (1), Malaysia (1), Mexico (1), Moldova (1), Netherlands (3), Nigeria (1), Norway (2), Poland (1), Portugal (1), Qatar (1), Saudi Arabia (3), Serbia (1), Slovenia (1), South Korea (3), Spain (4), Sweden (2), Thailand (3), Turkey (8), United Kingdom (10), United States (46), and Venezuela (1).

EDITOR-IN-CHIEF

Bo Jacobsson, *Gothenburg*

GUEST EDITORIAL BOARD MEMBERS

Wing P Chan, *Taipei*
Chie-Pein Chen, *Taipei*
Shi-Yann Cheng, *Yulin*
Song-Nan Chow, *Taipei*
Peng-Hui Wang, *Taipei*

MEMBERS OF THE EDITORIAL BOARD



Australia

Ashwini Chand, *Melbourne*
Steven D Fleming, *Brisbane*
Ankit Jain, *Coffs Harbour*
Marjan Khajehei, *Como*
Gavin Sacks, *Sydney*
Jing Sun, *Brisbane*



Austria

Susanne Huber, *Vienna*
Edgar Petru, *Graz*



Belgium

Marc FD Baay, *Antwerp*
Christophe Blockeel, *Brussels*
Yves Jacquemyn, *Edegem*
Ekaterine Tskitishvili, *Liege*
Jan Baptist Vermorken, *Edegem*



Brazil

Carlos KB Ferrari, *Barra do Garças*
Wellington P Martins, *Ribeirão Preto*
Fernando M Reis, *Belo Horizonte*
Maria Inês Rosa, *Criciúma*
Cicero de Andrade Urban, *Curitiba*



Canada

Emmanuel Bujold, *Québec*
Paul James Hoskins, *Vancouver*



Chile

Patricio E Donoso, *Santiago*



China

Cherng-Jye Jeng, *Nanjing*
Jian-Xin Li, *Nanjing*
Ernest Hung Yu Ng, *Hong Kong*
Dan Xie, *Guangzhou*



Egypt

Hesham E Abdel-Hady, *Mansoura*
Ahmed S El Hefnawy, *Mansoura*
Ahmed Nasr, *Assiut*



Finland

Johan O Fellman, *Helsinki*

Kari Juhani Syrjanen, *Turku*



France

Cherif Y Akladios, *Strasbourg*
Souhail Alouini, *Orleans*



Germany

Safaa H Al-Hasani, *Luebeck*



Greece

Georgios P Artsinevelos, *Athens*
Byron Asimakopoulos, *Alexandroupolis*
Anastasios Athanasopoulos, *Patra*
Panagiotis Christopoulos, *Athens*
Christos R Iavazzo, *Athens*
Ioannis E Messinis, *Larissa*
Athanasios PG Papatsoris, *Athens*
Kitty Pavlakis, *Athens*
Konstantinos A Toulis, *Thessaloniki*
Panagiotis PT Tsikouras, *Alexandroupolis*
Menelaos Zafrakas, *Thessaloniki*



Hungary

Jozsef Gabor Joo, *Budapest*



India

Chinmoy K Bose, *Kolkata*
Pralhad Kushtagi, *Mangalore*

Niraj N Mahajan, *Mumbai*



Iran

Hossein Fallahzadeh, *Yazd*
Abbas A Ghaderi, *Shiraz*
Ramesh Omranipour, *Tehran*



Israel

Zeev Blumenfeld, *Haifa*
Sorina Grisaru-Granovsky, *Jerusalem*
Alexander Ioscovich, *Jerusalem*
Marwan Odeh, *Nahariya*
Eyal Sheiner, *Beer-Sheva*
Johnny S Younis, *Tiberias*



Italy

SML Chamayou, *Sant'Agata Li Battiati*
Federico Coccolini, *Bergamo*
Erich Cosmi, *Padua*
Vassilios Fanos, *Caagliari*
Roberta Granese, *Messina*
Anna Maria Marconi, *Milano*
Filippo Murina, *Milan*
Felice Petraglia, *Siena*
Giuseppe Rizzo, *Rome*
Emilio Sacco, *Rome*
Giulio Aniello Santoro, *Treviso*
Andrea Tinelli, *Lece*
Emanuela Turillazzi, *Foggia*



Japan

Madoka Furuhashi, *Nagoya*
Takeshi Maruo, *Kobe*
Kaei Nasu, *Oita*
Yuzuru Niibe, *Sagamihara*
Kenzo Sonoda, *Fukuoka*
Yoshihito Yokoyama, *Hirosaki*



Jordan

Moamar I Al-Jefout, *Mutah*
Zouhair O Amarin, *Irbid*



Lithuania

Linas Rovas, *Klaipeda*



Malaysia

Geok Chin Tan, *Kuala Lumpur*



Mexico

Alfonso Dueñas-González, *Mexico City*



Moldova

Fanuel Lampiao, *Blantyre*



Netherlands

Marieke J Claas, *Utrecht*
Wendy Koster, *Utrecht*
Arnold-Jan Kruse, *Maastricht*



Nigeria

Chibuikwe O Chigbu, *Enugu*



Norway

Andrej M Grijbovski, *Oslo*
Svein Rasmussen, *Bergen*



Poland

Andrzej Winciewicz, *Kielce*



Portugal

Renato Manuel Natal Jorge, *Porto*



Qatar

Sajjad ur Rahman, *Doha*



Saudi Arabia

Ismail Al-Badawi, *Riyadh*
Mamdoh Eskandar, *Abha*
Hans-Juergen Schulten, *Jeddah*



Serbia

Miroslava G Gojnic Dugalic, *Belgrade*



Slovenia

Spela Smrkolj, *Ljubljana*



South Korea

Kwang-Hyun Baek, *Seongnam*
Min Hyung Jung, *Seoul*
Sue Kyung Park, *Seoul*



Spain

J de la Torre Fernandez de Vega, *Tenerife*
Antonio Pinero Madrona, *Murcia*
Santiago Palacios, *Madrid*

Faustino R Perez-Lopez, *Zaragoza*



Sweden

Eva Marie Wiberg-Itzel, *Stockholm*



Thailand

Pisake NA Lumbiganon, *Khon Kaen*
Vorapong Phupong, *Bangkok*
Viroj Wiwanitkit, *Bangkok*



Turkey

Metin Akbulut, *Denizli*
Cem Baykal, *Istanbul*
Husnu Celik, *Elazig*
Cem Dane, *Istanbul*
Polat Dursun, *Ankara*
Erdin İltter, *Istanbul*
Mehmet Kefeli, *Samsun*
Kamile Kukulu, *Antalya*



United Kingdom

Mohamed Abdel-fattah, *Aberdeen*
Suha Deen, *Nottingham*
Stergios K Doumouchtsis, *London*
Mona A El-Bahrawy, *London*
Alaa A El-Ghobashy, *Wolverhampton*
Ayman AA Ewies, *Birmingham*
Myra S Hunter, *London*
Paul D Losty, *Liverpool*
Tim Mark Reynolds, *Burton-on-Trent*
Ariel Zosmer, *London*



United States

Muktar H Aliyu, *Nashville*
M Robyn Andersen, *Seattle*
Priya R Bhosale, *Houston*
Donald P Braun, *Zion*
Chunxia Cao, *Gainesville*
Wally A Carlo, *Birmingham*
Linda R Chambliss, *Phoenix*
Teresa P Diaz-Montes, *Baltimore*
Steven M Donn, *Ann Arbor*
Omar F Duenas, *New York*
Marilyn B Escobedo, *Oklahoma*
Robert Freedman, *Detroit*
Sergio G Golombek, *Valhall*
Michael P Goodman, *Davis*
Diane M Harper, *Kansas*
Matthew H Ho, *Los Angeles*
Patricia B Hoyer, *Tucson*
Mei-Hua Huang, *Los Angeles*
William W Hurd, *Cleveland*
Gabor B Huszar, *New Haven*
Amer K Karam, *Los Angeles*
Justin P Lavin, *Akron*
Linda E May, *Kansas*
Zaher Merhi, *Bronx*
Nash S Moawad, *Gainesville*
Lisa Eileen Moore, *Albuquerque*
Robert D Moore, *Atlanta*

David Gardner Mutch, *St. Louis*
Nihar R Nayak, *Palo Alto*
Anita L Nelson, *Manhattan Beach*
Farr Nezhat, *New York*
Robert W Powers, *Pittsburgh*
Werner Schaefer, *Pittsburgh*
Gerald Phillip Schatten, *Pittsburgh*
Danny Joseph Schust, *Columbia*

Hen Yitzhak Sela, *New York*
Elizabeth S Ginsburg, *New York*
Sherri Lynn Stewart, *Atlanta*
Robert S Tan, *Houston*
Ping Tang, *Rochester*
Ihab Mohammed Usta, *New York*
Jian-Jun Wei, *Chicago*
Xiuquan Zhang, *Salt Lake*

Chengquan Zhao, *Pittsburgh*
Yulian Zhao, *Baltimore*
Wenxin Zheng, *Tucson*



Venezuela

María E Aponte-Rueda, *Caracas*



World Journal of Obstetrics and Gynecology

Contents

Quarterly Volume 2 Number 1 February 10, 2013

MINIREVIEWS

- 1 Burden of gynaecological cancers in developing countries
Iyoke CA, Ugwu GO

Contents

World Journal of Obstetrics and Gynecology
Volume 2 Number 1 February 10, 2013

APPENDIX I-V Instructions to authors

ABOUT COVER *World Journal of Obstetrics and Gynecology* Editorial Board Member, Danny Joseph Schust, MD, Associate Professor, Center for Reproductive Medicine and Fertility, Department of Obstetrics, Gynecology and Women's Health, University of Missouri School of Medicine, 500 North Keene Street, Suite 203, Columbia, MO 65201, United States

AIM AND SCOPE *World Journal of Obstetrics and Gynecology (World J Obstet Gynecol, WJOG, online ISSN 2218-6220, DOI: 10.5317)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJOG covers topics concerning pregnancy complications, obstetric surgical procedures, diagnostic imaging, endoscopy, reproductive endocrinology, tumors, pelvic diseases, evidence-based medicine, epidemiology and nursing.

We encourage authors to submit their manuscripts to *WJOG*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ ABSTRACTING *World Journal of Obstetrics and Gynecology* is now indexed in Digital Object Identifier.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Shuai Ma*
Responsible Electronic Editor: *Jun-Yao Li*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Su-Xin Gou*

NAME OF JOURNAL
World Journal of Obstetrics and Gynecology

ISSN
ISSN 2218-6220 (online)

LAUNCH DATE
June 10, 2012

FREQUENCY
Quarterly

EDITOR-IN-CHIEF
Bo Jacobsson, MD, PhD, Professor, Department of Obstetrics and Gynecology, Sahlgrenska University Hospital/Ostra, SE-416 85 Gothenburg, Sweden

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director

World Journal of Obstetrics and Gynecology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjog@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai,
Hong Kong, China
Fax: +852-65571888
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
February 10, 2013

COPYRIGHT

© 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2218-6220/g_info_20100722175812.htm.

ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

Burden of gynaecological cancers in developing countries

Chukwuemeka Anthony Iyoke, George Onyemaechi Ugwu

Chukwuemeka Anthony Iyoke, Department of Obstetrics and Gynaecology, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom

George Onyemaechi Ugwu, Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu 4000001, Nigeria

Author contributions: Iyoke CA conducted the literature review and drafted the manuscript; Ugwu GO reviewed and added intellectual content to the manuscript.

Correspondence to: Dr. Chukwuemeka Anthony Iyoke, Department of Obstetrics and Gynaecology, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom. caiyoke@yahoo.co.uk

Telephone: +44-117-9043422 Fax: +44-117-9043444

Received: June 22, 2012 Revised: November 7, 2012

Accepted: December 15, 2012

Published online: February 10, 2013

cal to gynaecological cancer control and reducing the burden of disease in many developing countries, the proposition assumes that resources are truly available for this investment. This may not be true. Many developing countries rely on foreign aids for developmental programmes and these aids have dwindled significantly with the current global economic meltdown.

© 2013 Baishideng. All rights reserved.

Key words: Gynaecological cancer; Cancer burden; Cancer mortality; Cancer morbidity; Cancer prevention

Iyoke CA, Ugwu GO. Burden of gynaecological cancers in developing countries. *World J Obstet Gynecol* 2013; 2(1): 1-7 Available from: URL: <http://www.wjgnet.com/2218-6220/full/v2/i1/1.htm> DOI: <http://dx.doi.org/10.5317/wjog.v2.i1.1>

Abstract

Approximately 1:4 of all cancers in women in developing countries (excluding non-melanoma skin cancer) is a gynaecological cancer. The gynaecological cancer burden in developing countries is huge primarily due to the high incidence and mortality of cervical cancer. Cervical cancer accounts for over 60% of the gynaecological cancer burden in developing countries despite being preventable by current technologies. This is due to the absence of effective nationally organized screening programmes in most developing countries. Institution of such programmes, therefore, has the potential to dramatically reduce gynaecological cancer burden in these countries. Subsidized human papilloma virus (HPV) vaccine and HPV typing as well as cheap screening techniques such as visual inspection aided with acetic acid hold the key to effective prevention of cervical cancer in these countries. This is because a significant proportion of patients in developing countries are unable to access and avail themselves of the few available preventive, diagnostic and treatment services because of poverty. Although, advocacy and the political will to invest in the development of human resources and healthcare infrastructure appear criti-

INTRODUCTION

Emerging global trend in the burden of cancer

Cancer is the second leading cause of death and disability worldwide, behind only heart disease^[1]. More people die from cancer every year than human immunodeficiency virus (HIV), tuberculosis and malaria combined^[1-4]. Contrary to about three decades ago when cancer was more prevalent in the developed world, the burden is shifting significantly to the developing countries. According to estimates by the International Agency for Research on Cancer (IARC), in 2008, 53% of the 12.7 million new cases of cancer and 63% of the 7.6 million cancer deaths occurred in developing countries^[3]. Three decades earlier, developing countries accounted for a mere 15% of global cancer burden^[4]. A recent report based on the IARC/GLOBOCAN 2002 world cancer statistics estimated that by the year 2020, about 10.25 million new cases of cancer would be diagnosed in the developing countries compared to 5.94 million in the developed countries^[1]. This trend is quite disturbing for many reasons including the fact that it will, no doubt, compound the already existing

formidable health and human developmental challenges posed by poverty, weak economies and high prevalences of communicable diseases in developing countries.

Explanations given for the increasing burden of cancer currently observed in developing countries have been based largely on epidemiological data and empirical observations. Reasons often cited include a shift in developing countries to Western lifestyle and behaviors such as cigarette smoking, low fiber/high fat diets and less physical activity^[5]; high prevalence of immunosuppressing conditions such as malnutrition, tuberculosis and HIV^[6]; high prevalence of oncogenic infections such as hepatitis B virus, HIV, hepatitis C virus, human papilloma virus (HPV), *Helicobacter pylori*^[5]. We observe that it is also possible that increasing health awareness in these countries has facilitated resort to orthodox medical care resulting in more persons with cancer reporting to hospitals for care, rather than seeking care from herbalists and other forms of alternative health care. Whether the increased documentation of cancer in developing countries is due to actual increase in disease incidence or reporting bias, cancer has become a new challenge to the health systems in developing countries.

Definition of operative concepts

Developing countries: For the purpose of this review, the term developing countries refers to countries classified by the World Bank as middle and low income countries in their classification of economies in 2009^[7]. These countries had gross national income per capita of USD 12 275 or below^[7]. Developing countries are by no means homogenous with respect to all indices of development. However, they are generally characterized by low standard of living (including poor access to health care, poor sanitation, poor access to safe drinking water and poor nutrition); underdeveloped industrial base and low human development index (including low level of literacy, low life expectancy, high infant and maternal mortality)^[8]. They include most countries of sub-Saharan Africa, South and South East Asia, Latin and South America.

Burden of cancer: For the burden of cancer, the epidemiological definition of the burden of cancer as described by Sankaranarayanan *et al*^[9] was used in this review. For economic burden, the economic definition described by Kim *et al*^[10] was adopted. Accordingly, the epidemiological indices of burden of gynaecological cancer used in this review include cancer incidence, mortality and case fatality while the economic definition involves the economic cost of the cancer (including medical costs, nonmedical costs and the cost due to loss of productivity)^[9,10].

Sources of data

The information contained in this review were obtained through electronic literature search conducted in major data bases including PubMed, Medline, EMBASE, Scopus, Cochrane database and central register of controlled

trials using the following search terms individually and in combination: gynaecological cancer, cancer in developing countries, burden of gynaecological cancer, cancer, cancer burden, cancer in sub-Saharan Africa, South Asia, Latin America, South America, the Caribbean, economic burden of cancer, cervical cancer, ovarian cancer, corpus cancer, vulval cancer, vaginal cancer, choriocarcinoma. All relevant peer-reviewed English language articles and publications were identified, retrieved and reviewed. We also obtained further articles by reviewing the bibliographies of the relevant published documents obtained in the primary search of databases. In addition to these, we consulted the website of the IARC for the current version of the GLOBOCAN world cancer statistics.

Aetiology of gynaecological cancers

In view of the importance of causative factors to any disease burden, it is appropriate to review the aetiological basis of gynaecological cancers. Gynaecological cancers include cancers of the ovary, fallopian tube, uterine body, cervix, vagina and vulva as well as choriocarcinoma which primarily come under the care of gynaecologists and gynaecological oncologists. This review excludes breast cancer because it comes under the specialty of general surgery in most developing countries.

Gynaecological cancers can be epidemiologically grouped into two with respect to aetiology. On the one hand are cervical, vaginal and vulvar cancers which share similarities, first in having known premalignant stages before the development of invasive cancer and secondly in their link with high risk human papilloma virus infection. Chronic infection with this virus is now known to induce premalignant changes in epithelial cells ultimately leading to cancer after several years^[11-13]. Human papilloma virus is a sexually transmitted disease. For cervical cancer, the relationship to HPV and the presence of a recognizable premalignant stage of the disease called cervical intraepithelial neoplasia (CIN) provide multiple planks for preventive efforts^[14-17]. Several co-factors are known to modify the effect of chronic HPV infection in the causation of cervical cancer and these include high parity, prolonged use of oral contraceptive pills, multiple sexual partners, cigarette smoking and early age at sexual debut^[11]. Vaginal and vulvar cancers are also known to evolve through premalignant phases called vaginal intraepithelial neoplasia and vulvar intraepithelial neoplasia respectively, but screening for these stages in the population is not currently recommended^[18-20].

On the other hand are ovarian, Fallopian tube and corpus cancers which do not have any known infective aetiology. Most cases of ovarian cancer occur spontaneously although genetic predisposition is responsible for ovarian cancer in 10% of cases^[21]. These hereditary ovarian cancers are associated with inherited germ line mutations in the *BRC A-1* and *BRC A-2* genes as well as the Lynch type 2 gene associated with hereditary non-polyposis colorectal cancer^[21]. Epithelial ovarian cancer is associated with a number of risk factors including a

family history of ovarian cancer, old age, postmenopausal status and use of hormone replacement therapy^[21]. Ovarian cancer has been traditionally thought to occur more in developed countries due to the higher prevalence of these epidemiological risk factors^[22]. However, it would appear that with recent global cancer estimates, the trend may be reversing^[1].

On its part, corpus cancer refers to cancer of the uterine body and is mainly endometrial cancer although rarely uterine sarcoma (leiomyosarcoma) may occur. Endometrial cancer is the third commonest gynaecological cancer in developing countries^[1,2]. It is a hormone-dependent cancer and is associated with several epidemiological risk factors, the most significant of which include unopposed estrogen, sedentary lifestyle and obesity^[23,24]. Endometrial cancer is thought to evolve through a premalignant stage called endometrial hyperplasia but the natural course of progression from endometrial hyperplasia to endometrial cancer is not clearly understood.

BURDEN OF GYNAECOLOGICAL CANCERS

General overview

The burden of gynaecological cancers in developing countries appears huge. In these countries, gynaecological cancers account for 25% of all new cancers diagnosed among women aged up to 65 years compared to 16% in the developed world^[25]. According to a recent report, developing countries accounted for 820 265 cases (77.7%) of global estimates for new cases of the commonest gynaecological cancers including cervical, corpus and ovarian cancer in 2009^[1]. This constituted 12.1% of the 6.8 million cases of cancer in developing countries^[1]. This review intends to explore the pattern, magnitude and significance of the current burden of gynaecological cancers in developing countries.

Specific gynaecological cancers

Cervical cancer: Cervical cancer is the commonest gynaecological malignancy in developing countries where organized screening programmes do not exist^[1,3]. According to the IARC, there were 453 531 cases of cervical cancer in developing countries in 2008 representing 89% of global estimates^[3]. Also 273 000 deaths occur worldwide every year due to cervical cancer out of which 83% occur in developing countries^[26]. Case fatality rates of cervical cancer are quite high in these countries with case fatalities up to 60% reported^[1]. Conversely in developed countries where nationally organized screening programmes exist, cervical cancer is not as common and case fatality rates are as low as 32%^[1]. About 80%-95% of cervical cancers are squamous cell carcinoma^[9].

Across different regions of the world, developing countries individually report heavy burdens of high incidences and mortality from cervical cancer. The highest incidence rates are found in Sub Saharan Africa, Latin America and the Caribbean, South Central and South

East Asia^[9]. A report from Nigeria gave the incidence of cervical cancer as 25/100 000 per year which translates to a disease burden for an estimated 32 million women in 2005 to about 8000 cases per year^[27]. A recent hospital based study in Lagos Nigeria showed that, overall, cancer was the leading cause of death among gynaecological inpatients and that cervical cancer contributed over 44% to all gynaecological mortality^[28]. South and South East Asia are thought to experience over 200 000 new cases of cervical cancer yearly (more than one-third of the global burden)^[26]. Age-adjusted cervical cancer mortality rates exceed 15 per 100 000 in most developing countries, with rates as high as 35/100 000 in East Africa^[9]. A nationwide survey in India published recently evaluated the cause of 122 429 deaths in 1.1 million randomly selected homes across the country between 2001 and 2003: cervical cancer made the highest contribution to cancer deaths among women at 17.5%^[29]. In Latin America and the Caribbean, Haiti, Nicaragua and Bolivia had the highest mortality due to cervical cancer with rates of 40, 28 and 22 percent respectively^[26]. The very high mortality rates of cervical cancer in developing countries are due to the fact that most patients present at advanced clinical stages of the disease, and to the fact that a significant proportion of patients do not receive or complete prescribed courses of treatment due to deficiencies in treatment availability, accessibility, and affordability^[9].

Ovarian and adnexal cancers: Fallopian tube cancers and extra ovarian primary peritoneal cancers are considered along with ovarian cancer because their biology and clinical characteristics are similar to ovarian cancer^[9]. Over 80% of cases of ovarian cancer are epithelial in origin^[22,30,31]. Ovarian cancer is the second commonest gynaecological cancer in developing countries^[9]. It accounts for 18.8% of all gynaecological cancers in developing countries and 28.7% in developed countries^[9]. Recent estimates indicated that of 240 476 cases of ovarian cancer in 2009, 155 835 (64.8%) occurred in developing countries compared to 84 641 in developed countries^[1]. Accounts that ovarian cancer is commoner in developed countries than in developing countries may not, therefore, be supported by the most current estimates. Ovarian cancer has a case-fatality rate of 59.2% in developing countries which is similar to the 54.8% in developed countries^[1]. The high case fatality rate of ovarian cancer is primarily due to the fact that the disease only becomes manifest in advanced stages of the disease^[30,31].

Corpus cancer: Corpus cancer is commoner in developed countries than in developing countries^[23]. In 2009, there were 236 643 cases worldwide out of which 113 486 occurred in developing countries representing approximately 48% of the global burden^[3]. Low incidences less than 4/100 000 are found in South Asia and Africa^[9]. More than 90% occur in women aged 50 years and above^[9]. It has a more favorable prognosis than Ovarian and Cervical cancers with 5-year survival rates around

70% in developing countries^[9].

Vaginal cancer: Vaginal cancer is rare and constitutes less than 2% of gynaecological cancers worldwide^[9]. Of 13 200 cases globally in 2002, 9000 (68%) occurred in developing countries^[9]. Incidence rates do not exceed 0.8/100 000 in any region of the world^[9]. Case fatality rate in developing countries is 44.7% compared to 15.4% in the developed world^[1]. More than 75% of cases occur in women older than 60 years^[9].

Vulva cancer: This constitutes 3% of gynaecological cancers worldwide^[9]. In 2002, there were 26 800 cases out of which 11 100 (41.4%) occurred in developing countries^[9]. Incidence rate is less than 1/100 000 in developing countries^[9]. More than 50% are seen in women over 70 years and more than two-thirds occur in the labia majora^[9].

Choriocarcinoma: This represents 0.6% of all gynaecological cancers^[9]. Approximately 5800 cases occurred worldwide in 2002 out of which 5400 (96.4%) occurred in developing countries^[9]. Incidence rates are highest in South East Asia where rates of (0.43-1.7)/100 000 are quoted compared to 0.04/100 000 in Africa and Europe^[9].

ECONOMIC BURDEN OF GYNAECOLOGICAL CANCERS

The economic burden of gynaecological cancers can be discussed at the level of individual patients and their families as well as the level of health systems and government. Accurate estimation of the actual economic burden of gynaecological cancers in developing countries is difficult because studies on the economic burden of gynaecological cancers in these countries are scanty. A few cross-sectional studies document the socio-economic impact of cervical cancer on individuals and families in some developing countries. Arrossi *et al.*^[32] in Argentina and Ohaeri *et al.*^[33] in Nigeria studied the socioeconomic and psychological impact of cervical cancer. The study in Argentina found that the socioeconomic impact of cervical cancer was considerable and that it had negative consequences on treatment compliance^[32]. It found that “in addition to facing pain, disability and fear of death, cervical cancer patients had to deal with increased treatment related expenses, loss of employment and consequent income, and changes in household responsibilities”^[32].

At the level of government and health systems, studies on the cost of cancer care and control are also scanty. A report based on calculations extrapolated from a study in Korea suggests a huge unmet need for funding of cancer care in developing countries. According to the report, the cost of new gynaecological cancers in developing countries in 2009 totalled USD 1.087 billion^[1]. This pales into insignificance when compared to the USD 11.913 billion spent in developed countries^[1]. The report clearly shows a huge funding gap in developing countries compared to developed countries^[1]. Africa which represents 15% of

global population contributes 6.4% of new cancer cases and accounts for a mere 0.3% global cancer costs^[1].

DISCUSSION

From the foregoing, it is clear that the burden of gynaecological cancer in developing countries is huge. Confronting with this challenge demands two vital planks of intervention: generation of representative and accurate data on cancer and the introduction or scaling up of preventive programmes and early detection of cancer through increased funding by all stakeholders.

Population data on cancer from developing countries are prone to inaccuracies. For instance the IARC relies on data from population-based cancer registries to estimate cancer incidences and mortality globally. Such registries are available in only 5% of developing countries - in parts of the developing world where cancer registries exist, they are either regional or hospital registries^[9]. In many countries of the developing world, data do not exist at all^[9]. For such countries, estimates are usually made from neighbouring countries. Variations in validity and extent of data from different countries are therefore unavoidable and the actual burden of cancers may be more or less than current quoted figures. Inaccurate data militates against accurate planning of policies and programmes for cancer care and control. It is therefore advocated that the establishment of population based cancer registries be made a priority policy for cancer control in developing countries.

Gynaecological cancer incidences are either expressed as an absolute number of cases per year which reflects the load of new patients diagnosed in a region or group, or as a rate in terms of number of new cases per 100 000 per year which represents the average risk of developing the disease in a population. Whichever way it is expressed, recent estimates of gynaecological cancer incidences in developing countries show that as much as 64% of the gynaecological cancer burden is due to cervical cancer^[31]. Cervical cancer control, therefore, holds the key to the reduction in overall gynaecological cancer burden in developing countries. With an estimated case-fatality rate of 55.1%^[1], cervical cancer is also the major contributor to gynaecological cancer mortality in developing countries.

Cervical cancer is preventable and curable in the very early stages of the disease. Fortunately, it has a very well known natural history characterized by a long pre-malignant phase which provides a good opportunity for preventive interventions. And among all gynaecological cancers, cervical cancer offers the greatest potential for prevention, early detection and cure^[9]. Evidence from the developed world shows that the high incidences of cervical cancer in developing countries are due to lack of or inadequate/inefficient existing screening programmes^[34,35].

The central role of HPV infection in the etiology of cervical cancer has led to the introduction of the HPV vaccine and HPV detection and typing in cervical screen-

ing^[36,37]. Already HPV vaccine is licensed for use in many developing countries, although the cost of the vaccine makes it generally unaffordable. In Nigeria, for instance, it costs the equivalent of USD 100.00 for a course of trivalent HPV vaccine - a country where over 70% of the population live on less than USD 1.0 per day. On its part, HPV detection and typing also require expensive equipment and highly skilled manpower that are not generally available in developing countries. Thus like cytology screening which requires a great input of human and material resources to sustain, nationally organized preventive programmes using HPV vaccine and detection may prove just too expensive for developing countries^[38].

It would appear therefore, that cervical cancer control in developing countries will require active scaling up of cheaper screening techniques such as visual inspection with acetic acid which has similar CIN detection rates compared to HPV testing and cervical cytology^[3]. Subsidizing the cost of HPV vaccine and HPV DNA testing by governments of these countries will go a long way to make them affordable to individuals. It has been suggested that linking testing or screening to treatment (screen and treat) without recourse to colposcopy or sophisticated laboratories would potentially prevent cervical cancer in large numbers of women in developing countries^[15,39,40].

In the case of ovarian cancer, the burden in developing countries appears to be rapidly evolving with recent estimates suggesting a greater burden than in developed countries^[1]. Except in about 10% of cases, ovarian cancer tends to occur spontaneously. The key to control of ovarian cancer appears to be early detection and treatment at the very early stages when cure may be theoretically possible^[13].

Screening for ovarian cancer has been evaluated recently by several large randomized controlled trials using assay of CA125 and transvaginal ultrasound^[41-43]. Results of the prostate, lung, colorectal, and ovarian cancer screening trial in the United States already published in 2011 suggest that whereas screening may decrease the stage at detection^[44] and thereby decrease case - specific mortality; it may not decrease disease specific mortality^[45]. The methodological flaws in these conclusions have however, been raised in a recent publication^[46] and the world awaits the publishing of the final results of the UKC-TOCS trial in 2015 to draw a conclusion as to whether ovarian cancer screening decreases mortality from the disease.

Endometrial cancer is the third commonest gynaecological cancer in developing countries. In order to be proactive in addressing the current and future burden of this cancer in developing countries, the risk factors that are modifiable such as obesity, sedentary lifestyles and use of unopposed estrogen/estrogen agonists have to be actively discouraged^[47,48]. Population screening for endometrial cancer is not yet recommended^[24] although early detection with transvaginal ultrasound scan using measurement of endometrial thickness in symptomatic women is practised in developed countries^[49]. Such practice requires

provision of ultrasonography and hysteroscopic facilities and manpower which are not yet freely available in developing countries.

The burden of vaginal and vulval cancers is small. Currently no evidence exists to support any screening tests^[50] although their association with HPV provides a window of opportunity for preventive interventions through HPV vaccination or typing. The task for developing countries in mounting early treatment or primary preventive interventions will be similar to the challenges faced with cervical cancer.

In conclusion, there is a high incidence and mortality from gynaecological cancers in developing countries due primarily to the failure of these countries to mount effective nationally organized screening programmes for cervical cancer. A huge unmet need for funding for cancer care and control exists in these countries. "The human right to life, to prevention of suffering, and to education are all key rights linked to improving the control of cervical cancer in resource poor parts of the world"^[51]. The resources needed to provide adequately for gynaecological cancer care in many developing countries demands that increased funding is critically needed^[52]. Scaling up of cheap sustainable and effective preventive interventions against cervical cancer will potentially decrease the burden of gynaecological cancer in developing countries. Nationally organized HPV vaccination and low cost screening programmes subsidized by funding from governments and donor agencies are key to this intervention.

REFERENCES

- 1 **The Economist Intelligence Unit.** Breakaway: The global burden of cancer-challenges and opportunities. The Economist, 2009
- 2 **Parkin DM, Bray F, Ferlay J, Pisani P.** Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
- 3 **International Agency for Research on Cancer.** GLOBOCAN 2008 Fast stats. Available from: URL: <http://www.globocan.iarc.fr/>. Accessed: April 24, 2012
- 4 **Boyle P, Levin B.** World cancer report 2008. Lyon: International Agency for Research on Cancer, 2008
- 5 **Wilson CM, Tobin S, Young RC.** The exploding worldwide cancer burden: the impact of cancer on women. *Int J Gynecol Cancer* 2004; **14**: 1-11 [PMID: 14764024 DOI: 10.1111/j.1048-891x.2004.14178.x]
- 6 **Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW.** Cancer care challenges in developing countries. *Cancer* 2012; **118**: 3627-3635 [PMID: 22223050 DOI: 10.1002/cncr.26681]
- 7 **World bank.** World Development indicators. Available from: URL: http://data.worldbank.org/data-catalog/world-development-indicators?cid=GDP_WDI. Accessed: April 24, 2012
- 8 **United Nations Statistics Division.** Composition of macrogeographical (continental) regions, geographical sub regions and selected economies and other groupings ("Footnote c"). United Nations, 2008
- 9 **Sankaranarayanan R, Ferlay J.** Worldwide burden of gynaecological cancer: the size of the problem. *Best Pract Res Clin Obstet Gynaecol* 2006; **20**: 207-225 [PMID: 16359925 DOI: 10.1016/j.bpobgyn.2005.10.007]
- 10 **Kim SG, Hahm MI, Choi KS, Seung NY, Shin HR, Park**

- EC. The economic burden of cancer in Korea in 2002. *Eur J Cancer Care* (Engl) 2008; **17**: 136-144 [PMID: 18302650 DOI: 10.1111/j.1365-2354.2007.00818.x]
- 11 **Bosch FX**, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. *J Natl Cancer Inst* 1995; **87**: 796-802 [PMID: 7791229 DOI: 10.1093/jnci/87.11.796]
 - 12 **Walboomers JM**, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; **189**: 12-19 [PMID: 10451482 DOI: 10.1002/(SICI)1096-9896(199909)189]
 - 13 **Bosch FX**, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol* 2002; **55**: 244-265 [PMID: 11919208 DOI: 10.1136/jcp.55.4.244]
 - 14 **Denny L**. Cytological screening for cervical cancer prevention. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 189-196 [PMID: 22071306 DOI: 10.1016/j.bpobgyn.2011.08.001]
 - 15 **Wright TC**, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 197-208 [PMID: 22385539 DOI: 10.1016/j.bpobgyn.2011.11.004]
 - 16 **Bhatla N**, Singla S, Awasthi D. Human papillomavirus deoxyribonucleic acid testing in developed countries. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 209-220 [PMID: 22154228 DOI: 10.1016/j.bpobgyn.2011.11.003]
 - 17 **Sankaranarayanan R**, Nessa A, Esmay PO, Dangou JM. Visual inspection methods for cervical cancer prevention. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 221-232 [PMID: 22075441 DOI: 10.1016/j.bpobgyn.2011.08.003]
 - 18 **American College of Obstetrics and Gynecology**. ACOG Committee Opinion No. 509: Management of vulvar intraepithelial neoplasia. *Obstet Gynecol* 2011; **118**: 1192-1194 [PMID: 22015906 DOI: 10.1097/AOG.0b013e31823b17c2]
 - 19 **Jones RW**, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. *Obstet Gynecol* 2005; **106**: 1319-1326 [PMID: 16319258 DOI: 10.1097/01.AOG.0000187301.76283.7f]
 - 20 **Pearson JM**, Feltman RS, Twiggs LB. Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention. *Womens Health* (Lond Engl) 2008; **4**: 143-150 [PMID: 19072516 DOI: 10.2217/17455057.4.2.143]
 - 21 **Jelovac D**, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J Clin* 2011; **61**: 183-203 [PMID: 21521830 DOI: 10.3322/caac.20113]
 - 22 **Hennessy BT**, Coleman RL, Markman M. Ovarian cancer. *Lancet* 2009; **374**: 1371-1382 [PMID: 19793610 DOI: 10.1016/S0140-6736(09)61338-6]
 - 23 **Fader AN**, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. *Gynecol Oncol* 2009; **114**: 121-127 [PMID: 19406460 DOI: 10.1016/j.ygyno.2009.03.039]
 - 24 **Van den Bosch T**, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 257-266 [PMID: 22078749 DOI: 10.1016/j.bpobgyn]
 - 25 **Ferlay J**, Bray F, Norman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide. International Agency for Research on Cancer, 2008
 - 26 **Ferlay J**, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and Prevalence worldwide. GLOBOCAN 2002, IARC Cancer base 5(2.0). Lyon: IARC Press, 2004
 - 27 **Adewole IF**, Benedet JL, Crain BT, Follen M. Evolving a strategic approach to cervical cancer control in Africa. *Gynecol Oncol* 2005; **99**: S209-S212 [PMID: 16202445 DOI: 10.1016/j.ygyno.2005.07.086]
 - 28 **Anorlu RI**, Obodo K, Makwe CC. Cancer mortality among patients admitted to gynecological wards at Lagos University Teaching Hospital, Nigeria. *Int J Gynaecol Obstet* 2010; **110**: 268-269 [PMID: 20510415 DOI: 10.1016/j.ijgo.2010.03.038]
 - 29 **Dikshit R**, Gupta PC, Ramasundarathette C, Gajalakshmi V, Aleksandrowicz L, Badwe R, Kumar R, Roy S, Suraweera W, Bray F, Mallath M, Singh PK, Sinha DN, Shet AS, Gelband H, Jha P. Cancer mortality in India: a nationally representative survey. *Lancet* 2012; **379**: 1807-1816 [PMID: 22460346 DOI: 10.1016/S0140]
 - 30 **Bast RC**, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. *Nat Rev Cancer* 2009; **9**: 415-428 [PMID: 19461667 DOI: 10.1038/nrc2644]
 - 31 **Gubbels JA**, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. *J Ovarian Res* 2010; **3**: 8 [PMID: 20350313 DOI: 10.1186/1757-2215-3-8]
 - 32 **Arrossi S**, Matos E, Zengarini N, Roth B, Sankaranarayanan R, Parkin M. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. *Gynecol Oncol* 2007; **105**: 335-340 [PMID: 17258801 DOI: 10.1016/j.ygyno.2006.12.010]
 - 33 **Ohaeri JU**, Campbell OB, Ilesanmi AO, Omigbodun AO. The psychosocial burden of caring for some Nigerian women with breast cancer and cervical cancer. *Soc Sci Med* 1999; **49**: 1541-1549 [PMID: 10515635 DOI: 10.1016/S0277-9536(99)00223-3]
 - 34 **Gustafsson L**, Pontén J, Bergström R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. *Int J Cancer* 1997; **71**: 159-165 [PMID: 9139836 DOI: 10.1002/(SICI)1097-0215(19970410)71]
 - 35 **Gustafsson L**, Pontén J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. *Cancer Causes Control* 1997; **8**: 755-763 [PMID: 9328198]
 - 36 **Sankaranarayanan R**, Nene BM, Shastri SS, Jayant K, Mungwong R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. *N Engl J Med* 2009; **360**: 1385-1394 [PMID: 19339719 DOI: 10.1056/NEJMoa0808516]
 - 37 **Brown AJ**, Trimble CL. New technologies for cervical cancer screening. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 233-242 [PMID: 22119058 DOI: 10.1016/j.bpobgyn.2011.11.001]
 - 38 **Kulasingam S**, Havrilesky L. Health economics of screening for gynaecological cancers. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 163-173 [PMID: 22138003 DOI: 10.1016/j.bpobgyn.2011.10.013]
 - 39 **Armstrong EP**. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. *J Manag Care Pharm* 2010; **16**: 217-230 [PMID: 20331326]
 - 40 **Goldie SJ**, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC. Cost-effectiveness of cervical-cancer screening in five developing countries. *N Engl J Med* 2005; **353**: 2158-2168 [PMID: 16291985]
 - 41 **Buys SS**, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. *Am J Obstet Gynecol* 2005; **193**: 1630-1639 [PMID: 16260202 DOI: 10.1016/j.ajog.2005.05.005]
 - 42 **Menon U**, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitiv-

- ity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009; **10**: 327-340 [PMID: 19282241 DOI: 10.1016/S1470-2045(09)70026-9]
- 43 **Kobayashi H**, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T. A randomized study of screening for ovarian cancer: a multicenter study in Japan. *Int J Gynecol Cancer* 2008; **18**: 414-420 [PMID: 17645503 DOI: 10.1111/j.1525-1438.2007.01035.x]
- 44 **Pavlik EJ**, van Nagell JR. Ovarian cancer screening--what women want. *Int J Gynecol Cancer* 2012; **22** Suppl 1: S21-S23 [PMID: 22543915]
- 45 **Buys SS**, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011; **305**: 2295-2303 [PMID: 21642681 DOI: 10.1001/jama.2011.766]
- 46 **Menon U**. Ovarian cancer screening has no effect on disease-specific mortality: commentary on the mortality results of the PLCO trial. *Evid Based Med* 2012; **17**: 47-48 [DOI: 10.1136/ebm.2011.100163]
- 47 **Gehrig PA**, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? *Gynecol Oncol* 2008; **111**: 41-45 [PMID: 18694588]
- 48 **Soliman PT**, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. *Obstet Gynecol* 2005; **105**: 575-580 [PMID: 15738027 DOI: 10.1097/01.AOG.0000154151.14516.f7]
- 49 **Havrilesky LJ**, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. *Am J Obstet Gynecol* 2009; **200**: 640.e1-640.e8 [PMID: 19380121]
- 50 **Eva LJ**. Screening and follow up of vulval skin disorders. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 175-188 [PMID: 22189088 DOI: 10.1016/j.bpobgyn.2011.11.005]
- 51 **Basile S**, Angioli R, Mancini N, Palaia I, Plotti F, Benedetti Panici P. Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. *Int J Gynecol Cancer* 2006; **16**: 1491-1497 [PMID: 16884356 DOI: 10.1111/J.1525-1438.2006.00819.x]
- 52 **Cain JM**, Ngan H, Garland S, Wright T. Control of cervical cancer: women's options and rights. *Int J Gynaecol Obstet* 2009; **106**: 141-143 [PMID: 19535071 DOI: 10.1016/j.ijgo.2009.03.027]

P- Reviewer Schust DJ S- Editor Gou SX L- Editor A
E- Editor Li JY



GENERAL INFORMATION

World Journal of Obstetrics and Gynecology (*World J Obstet Gynecol*, *WJOG*, online ISSN 2218-6220, DOI: 10.5317) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aim and scope

WJOG covers topics concerning pregnancy complications, obstetric surgical procedures, diagnostic imaging, endoscopy, reproductive endocrinology, tumors, pelvic diseases, evidence-based medicine, epidemiology and nursing.

We encourage authors to submit their manuscripts to *WJOG*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJOG is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJOG* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems

that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in obstetrics and gynecology; (12) Brief Articles: To briefly report the novel and innovative findings in obstetrics and gynecology; (13) Meta-Analysis: To evaluate the clinical effectiveness in obstetrics and gynecology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJOG*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of obstetrics and gynecology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Obstetrics and Gynecology

ISSN

ISSN 2218-6220 (online)

Frequency

Quarterly

Editor-in-Chief

Bo Jacobsson, MD, PhD, Professor, Department Obstetrics and Gynecology, Sahlgrenska University Hospital/Ostra, SE-416 85 Gothenburg, Sweden

Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Obstetrics and Gynecology

Editorial Department: Room 903, Building D,

Ocean International Center,

Instructions to authors

No. 62 Dongsihuan Zhonglu,
Chaoyang District, Beijing 100025, China
E-mail: wjog@wjgnet.com
<http://www.wjgnet.com>
Telephone: +86-10-85381891
Fax: +86-10-8538-1893

Publisher

Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpoffice@wjgnet.com
<http://www.wjgnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893

Representative office

USA Office
8226 Regency Drive,
Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2218-6220/g_info_20100722175812.htm.

Indexed and Abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJOG* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained dur-

ing mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2218-6220office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2218-6220/g_info_20100722175812.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjog@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJOG*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g., 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle

Instructions to authors

to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic

programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 $\mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2218-6220/g_info_20100724062131.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the

link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2219-2808/g_info_20100725073726.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2218-6220/g_info_20100724061942.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJOG will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Publication fee

WJOG is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

